Monomorphic Ventricular Tachycardia Due to Protease Inhibitor Intoxication by Atazanavir

Overview

Journal Clin Exp Emerg Med

Specialty Emergency Medicine

Date 2018 May 1

PMID 29706057

Authors

Byunghyun Kim

Kyung Su Kim

Affiliations

Soon will be listed here.

Abstract

Atazanavir is a protease inhibitor approved for use in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus infection. Atazanavir and other protease inhibitors can sometimes induce corrected QT prolongation and ventricular arrhythmia. A 40-year-old man with no comorbidities, except human immunodeficiency virus 1 infection, presented with palpitations 3 days after an overdose of 150 caps of atazanavir, with suicidal intent. His initial electrocardiogram showed monomorphic ventricular tachycardia, and hyperbilirubinemia was observed in his initial blood test. Immediately after magnesium sulfate infusion, his ventricular tachycardia was converted into junctional bradycardia with prolonged corrected QT. After 3 days of close observation in the intensive care unit, the corrected QT prolongation and hyperbilirubinemia were normalized.

References

Yap Y, Camm A . Drug induced QT prolongation and torsades de pointes. Heart. 2003; 89(11):1363-72. PMC: 1767957. DOI: 10.1136/heart.89.11.1363. View

Uglietti A, Novati S, Gulminetti R, Maserati R . Correlations between atazanavir C(trough )and hyperbilirubinemia: a case report. J Med Case Rep. 2010; 3:9307. PMC: 2803830. DOI: 10.1186/1752-1947-3-9307. View

Allen B, Brodsky M, Capparelli E, Luckett C, ISERI L . Magnesium sulfate therapy for sustained monomorphic ventricular tachycardia. Am J Cardiol. 1989; 64(18):1202-4. DOI: 10.1016/0002-9149(89)90880-1. View

Kang C, Bang J, Cho S, Kim K, Lee H, Ryu B . Suicidal ideation and suicide attempts among human immunodeficiency virus-infected adults: differences in risk factors and their implications. AIDS Care. 2015; 28(3):306-13. DOI: 10.1080/09540121.2015.1093593. View

Samji H, Cescon A, Hogg R, Modur S, Althoff K, Buchacz K . Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013; 8(12):e81355. PMC: 3867319. DOI: 10.1371/journal.pone.0081355. View

Gallagher D, Kieran J, Sheehan G, Lambert J, Mahon N, Mallon P . Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reports. Clin Infect Dis. 2008; 47(3):e36-8. DOI: 10.1086/589869. View

Catalan J, Harding R, Sibley E, Clucas C, Croome N, Sherr L . HIV infection and mental health: suicidal behaviour--systematic review. Psychol Health Med. 2011; 16(5):588-611. DOI: 10.1080/13548506.2011.582125. View

Croom K, Dhillon S, Keam S . Atazanavir: a review of its use in the management of HIV-1 infection. Drugs. 2009; 69(8):1107-40. DOI: 10.2165/00003495-200969080-00009. View

Priori S, Schwartz P, Napolitano C, Bloise R, Ronchetti E, Grillo M . Risk stratification in the long-QT syndrome. N Engl J Med. 2003; 348(19):1866-74. DOI: 10.1056/NEJMoa022147. View

10.

Zlotorzynska M, Spaulding A, Messina L, Coker D, Ward K, Easley K . Retrospective cohort study of cancer incidence and mortality by HIV status in a Georgia, USA, prisoner cohort during the HAART era. BMJ Open. 2016; 6(4):e009778. PMC: 4838674. DOI: 10.1136/bmjopen-2015-009778. View

11.

Anson B, Weaver J, Ackerman M, Akinsete O, Henry K, January C . Blockade of HERG channels by HIV protease inhibitors. Lancet. 2005; 365(9460):682-6. DOI: 10.1016/S0140-6736(05)17950-1. View

12.

Ly T, Ruiz M . Prolonged QT interval and torsades de pointes associated with atazanavir therapy. Clin Infect Dis. 2007; 44(6):e67-8. DOI: 10.1086/511875. View